Skip to main content

Intermittent Theta-Burst Stimulation for Adolescent Depression: A Randomized Trial

In brief

Targeted brain stimulation lowered teen depression scores 6 points more than sham

In a randomized trial of 56 adolescents whose depression had not responded to at least one antidepressant, 10 weekday sessions of targeted brain stimulation produced a 6.4-point greater reduction in depression scores than sham at one month. Anhedonia also improved more, and no serious adverse events occurred; larger studies must confirm how durable and clinically meaningful the benefits are.

Journal
Pediatrics (Q1)
Published
19 November 2026
Study design
Randomized controlled trial
Evidence level
Level 1, High (CEBM 1b)
Authors
Xiaoxia Duan, Yujie Tao, Mingjing Situ, Di Jing, Pei Liu, Zhaozhi Yang, et al.
PMID
43051241
DOI
10.1542/peds.2026-077541

Why clinicians should know about it

  • Picked for Psychiatry and Mental Health (paper of the day, 19 November 2026): Randomized trial tests iTBS for treatment-resistant adolescent depression

Abstract

BACKGROUND AND OBJECTIVES: Intermittent theta-burst stimulation (iTBS) is effective for adult depression, but evidence in adolescents is limited. Anhedonia predicts poor outcomes and correlates with reduced nucleus accumbens-prefrontal connectivity. This trial aimed to determine whether connectivity-guided iTBS targeting this circuit could alleviate depressive symptoms and anhedonia in adolescents with major depressive disorder (MDD) and whether anhedonia improvement mediates the effect. METHODS: This randomized, double-blind, sham-controlled trial enrolled adolescents aged 10 to 17 years with MDD who did not respond to at least 1 adequate antidepressant trial. Active iTBS (1800 pulses/session, 80% resting motor threshold, once daily for 10 weekdays) targeted the left dorsolateral prefrontal cortex voxel with the strongest resting-state functional connectivity to the contralateral nucleus accumbens; sham group received identical procedures. Primary outcome was Beck Depression Inventory-II (BDI-II) score change (baseline to 1-month posttreatment). Secondary outcomes were Snaith-Hamilton Pleasure Scale scores, anxiety, and response/remission rates. Exploratory analyses used causal mediation models. RESULTS: Of 60 screened participants, 56 were randomized (mean age, 14.7 years; 75% female). Active iTBS reduced BDI-II score more than sham (mean change, 9.46 vs 3.04; difference, 6.43; d = 0.87; P = .002), with significant treatment-by-time interaction (P = .03). Anhedonia improvement favored active iTBS at posttreatment (difference 4.50; d = 0.89; P = .002) and 1-month follow-up (difference 7.46; d = 1.22; P < .001). Mediation analysis showed anhedonia improvement mediated the 1-month effect (indirect -2.38 [95% CI, -5.55 to -0.45]; 42.1% mediation [95% CI, 19.1%-307.5%]). No serious adverse events occurred. CONCLUSIONS AND RELEVANCE: Connectivity-guided iTBS significantly reduced depressive symptoms and anhedonia in adolescents with MDD, with effects significantly mediated by anhedonia improvement. Further research into this approach as a precision intervention for adolescent depression is warranted.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.